ETEX Corporation Announces Distribution Agreement with Alph...( CAMBRIDGE Mass. Nov. 5 /- ETEX Corpor...),Health

CAMBRIDGE, Mass., Nov. 5 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today a distribution agreement with Alphatec Spine, of Carlsbad, California. Alphatec Spine will market and sell ETEX's proprietary bone graft substitute portfolio on a non-exclusive basis in the United States.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

Initial sales and marketing efforts will be focused on EquivaBone®, ETEX's proprietary, certified osteoinductive hybrid bone graft. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

Subsequent to regulatory clearance, Alphatec will market and sell ETEX's novel porous bone graft substitute, CarriGen®. CarriGen is a synthetic bone substitute that utilizes the same proprietary nanocrystalline calcium phosphate technology that is found in EquivaBone. CarriGen is currently under a 510(k) review with the F.D.A., and is not available for sale. As a pure synthetic, CarriGen is designed to set hard, and has compressive strength comparable to that of cancellous bone. CarriGen has high porosity which allows it to absorb saline and/or blood when mixed. Alphatec Spine expects to distribute CarriGen in the United States and Europe in the first half of 2010.

Brian Ennis, President and CEO of ETEX Corporation, comments: "We are quite impressed with Alphatec's team, technology platforms, and extraordinary growth in a challenging economic environment. The breadth and versatility in ETEX Corporation's rapidly expanding orthobiologic portfolio is extremely synergistic with Alphatec's market initiatives. We view this distribution agreement as the first phase of a partnership with substantial upside potential which may evolve i
'/>"/>